ACE2 and cancer: Variations in angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2, A disintegrin and metalloprotease 17 (ADAM17), and Dedicator of cytokinesis 2 (DOCK2) levels, influenced by cancer types, differ among populations [48–50].